GSK delivered solid Q4 2025 results with revenue growth led by Specialty Medicines, higher operating profit, and strong cash generation.

GSK reported £8.55 billion in revenue and £2.2 billion in net income for Q3 2025, with EPS per ordinary share estimated at £0.585 after converting from reported ADS values. Specialty Medicines saw double-digit growth while Vaccines and General Medicines remained steady.

GSK posted a robust quarter with £7.99 billion in revenue and £1.89 billion in net income. EPS rose to 46.5p as operating profit margins improved, supported by growth in Specialty Medicines and pipeline progress.

GSK delivered solid performance in Q1 2025, led by double-digit growth in Specialty Medicines, especially in HIV, Oncology, and Immunology. Operating income and net income saw major increases, supported by lower contingent consideration charges and strong R&D momentum.